RNXT

RenovoRx, Inc. (RNXT) | Rumor.io

RenovoRx

RNXT

Attention (50-day avg)0%

Attention rank (50-day avg)#1,745

Bullish sentiment (50-day avg)89%

Price to earnings ratio-4.84

Market capitalization70M

Earnings per share-0.29

Dividend yield (TTM)—

Revenue (annual)1.1M

Net income (annual)-11.2M

Social

What share of all stock conversation is about RNXT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 14

RenovoRx, Inc. (RNXT) has reported record second-quarter revenue driven by increasing commercial demand for its RenovoCath device.
The company is expected to complete its Phase III TIGeR-PaC trial in the first half of 2027, with initial top-line data availability expected in the second half of 2027.
RenovoRx's technology has the potential for treatment across a broader range of solid tumors, with the company's peak revenue estimated at $400 million and more use cases expected.

Generated by AI

Sentiment

Of the messages about RNXT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	50% -50	82.22% -16.43	85.9% -9.93
Bearish	—	50% new	17.78% +16.43	14.1% +9.93

Bullish· Aug 15

RenovoRx's RenovoCath has expanded its reach to 13 cancer centers, up from 5 last month, with a 65% reduction in negative side effects.
The company has a strong cash position of $12.3M to fuel growth and is targeting a massive market opportunity in pancreatic cancer treatment, which is expected to grow from $3B+ to $10B+ by 2030.
RenovoRx has established a bottom near $0.95 after a post-earnings selloff, with a bullish hammer candle forming, and is expected to scale quickly with its commercialization momentum and Phase III trial progress.

Bearish· Jun 29

$RNXT is being shorted aggressively, with 10K short shares just covered.
The stock's price movement is not being driven by interest in its pancreatic cancer treatment, but rather by short sellers.
Shorting $RNXT may be seen as a negative reflection on one's own life, with some users expressing hope that short sellers will "waste away in front of their loved ones".

Generated by AI

Topics

Of the messages about RNXT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	100%	77.27%	7.82%
Announcements	—	0%	9.09%	83.3%
Analysts	—	0%	9.09%	3.37%
Earnings	—	0%	0%	3.55%
Macro	—	0%	4.55%	1.95%
Controversies	—	0%	0%	0%

Announcements· Aug 15

RenovoRx reported Q2 2025 revenue of $422K, a 27% beat from estimates, and expanded its RenovoCath commercial rollout to 13 cancer centers.
The company also announced a new registry study and launched its Phase III TIGeR-PaC trial for pancreatic cancer, which has received a positive recommendation from the independent Data Monitoring Committee.
RenovoRx has a cash runway of $12.3M and is targeting a $1B market opportunity in the pancreatic cancer treatment market, which is expected to grow to $10B by 2030.

Technical Analysis· Nov 11

$RNXT is forming a cup handle pattern on the 10-minute chart, and a bullish harami on the 4-hour chart.
The stock's daily chart looks good, with solid levels built, and it's going to retest highs for the day.
$RNXT is breaking through resistance at $9, which could lead to exciting price movements, and is also showing a healthy pullback with a bullish outlook to $10.

Generated by AI

Community

Of the messages about RNXT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	25%	26.07%	31.06%
Newcomers	—	75%	73.93%	68.94%

Sep 9

Newcomers are focused on RenovoRx, Inc.'s ($RNXT) potential for commercial growth, with one user citing a possible $1.5M quarter in product sales and another expecting the stock to grow to $7 within a year to 4-5 years.
Some users are optimistic about the company's future, with one predicting a spike in growth and another expecting the stock to reach $3 within 6 months to 1 year, while others are bearish, warning of a potential decline to $1 and a "pump and dump" stock.
One user is focused on the mechanics of short positions, explaining the differences between hedged and naked shorts and warning about the risks of naked short positions, while another user is buying the dip and trying to stay disciplined despite the stock's recent volatility.

Generated by AI

News

RenovoRx at H.C. Wainwright conference: commercial growth builds

15d agoInvesting.com

RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline

RenovoRx (NASDAQ:RNXT) will use its H. C.

27d agoYahoo Finance

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

MOUNTAIN VIEW, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York P

27d agoYahoo! Finance Canada

RenovoRx publishes pharmacokinetic data from Phase III trial

1mo agoInvesting.com

RenovoRx regains Nasdaq minimum bid price compliance

1mo agoInvesting.com

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it has received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq

1mo agoYahoo! Finance Canada

Also Discussed

Investors talking about RNXT also mention

#	Name	Attention
1	Longeveron Inc. Class A Common StockLGVN	0%0
2	Better Therapeutics, Inc.BTTX	0%new
3	NRx Pharmaceuticals, Inc.NRXP	0%-0.01
4	NeuroOne Medical Technologies CorporationNMTC	0%0
5	American BriVision (Holding) CorporationABVC	0%+0
6	Pasithea Therapeutics Corp.KTTA	0%0
7	EFTR - eFFECTOR Therapeutics, Inc.	——
8	Biofrontera Inc.BFRI	0%0
9	Virpax Pharmaceuticals Inc.VRPX	0%0
10	iSpecimen Inc.ISPC	0%0

RenovoRx, Inc.

Healthcare
Biotechnology

RenovoRx, Inc. is a life sciences company focused on targeted oncology therapies and localized drug delivery for cancer treatment. Its core offering includes RenovoCath, an FDA-cleared local drug delivery device designed to deliver chemotherapy directly to tumor sites while limiting exposure to healthy tissue. The company also develops its Trans-Arterial Micro-Perfusion therapy platform, which is intended for precise intra-arterial delivery of cancer treatments in solid tumors. RenovoRx’s work centers on addressing high unmet medical needs in oncology, with particular emphasis on improving how therapies are administered in clinical settings. The company operates at the intersection of medical technology and biopharmaceutical development, serving the broader cancer care market through device-enabled drug delivery solutions.

Website

Location

2570 West El Camino Real

Mountain View, CA, 94040

United States

Social

What share of all stock conversation is about RNXT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 14

RenovoRx, Inc. (RNXT) has reported record second-quarter revenue driven by increasing commercial demand for its RenovoCath device.
The company is expected to complete its Phase III TIGeR-PaC trial in the first half of 2027, with initial top-line data availability expected in the second half of 2027.
RenovoRx's technology has the potential for treatment across a broader range of solid tumors, with the company's peak revenue estimated at $400 million and more use cases expected.

Generated by AI

Sentiment

Of the messages about RNXT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	50% -50	82.22% -16.43	85.9% -9.93
Bearish	—	50% new	17.78% +16.43	14.1% +9.93

Bullish· Aug 15

RenovoRx's RenovoCath has expanded its reach to 13 cancer centers, up from 5 last month, with a 65% reduction in negative side effects.
The company has a strong cash position of $12.3M to fuel growth and is targeting a massive market opportunity in pancreatic cancer treatment, which is expected to grow from $3B+ to $10B+ by 2030.
RenovoRx has established a bottom near $0.95 after a post-earnings selloff, with a bullish hammer candle forming, and is expected to scale quickly with its commercialization momentum and Phase III trial progress.

Bearish· Jun 29

$RNXT is being shorted aggressively, with 10K short shares just covered.
The stock's price movement is not being driven by interest in its pancreatic cancer treatment, but rather by short sellers.
Shorting $RNXT may be seen as a negative reflection on one's own life, with some users expressing hope that short sellers will "waste away in front of their loved ones".

Generated by AI

Topics

Of the messages about RNXT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	100%	77.27%	7.82%
Announcements	—	0%	9.09%	83.3%
Analysts	—	0%	9.09%	3.37%
Earnings	—	0%	0%	3.55%
Macro	—	0%	4.55%	1.95%
Controversies	—	0%	0%	0%

Announcements· Aug 15

RenovoRx reported Q2 2025 revenue of $422K, a 27% beat from estimates, and expanded its RenovoCath commercial rollout to 13 cancer centers.
The company also announced a new registry study and launched its Phase III TIGeR-PaC trial for pancreatic cancer, which has received a positive recommendation from the independent Data Monitoring Committee.
RenovoRx has a cash runway of $12.3M and is targeting a $1B market opportunity in the pancreatic cancer treatment market, which is expected to grow to $10B by 2030.

Technical Analysis· Nov 11

$RNXT is forming a cup handle pattern on the 10-minute chart, and a bullish harami on the 4-hour chart.
The stock's daily chart looks good, with solid levels built, and it's going to retest highs for the day.
$RNXT is breaking through resistance at $9, which could lead to exciting price movements, and is also showing a healthy pullback with a bullish outlook to $10.

Generated by AI

Community

Of the messages about RNXT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	25%	26.07%	31.06%
Newcomers	—	75%	73.93%	68.94%

Sep 9

Newcomers are focused on RenovoRx, Inc.'s ($RNXT) potential for commercial growth, with one user citing a possible $1.5M quarter in product sales and another expecting the stock to grow to $7 within a year to 4-5 years.
Some users are optimistic about the company's future, with one predicting a spike in growth and another expecting the stock to reach $3 within 6 months to 1 year, while others are bearish, warning of a potential decline to $1 and a "pump and dump" stock.
One user is focused on the mechanics of short positions, explaining the differences between hedged and naked shorts and warning about the risks of naked short positions, while another user is buying the dip and trying to stay disciplined despite the stock's recent volatility.

Generated by AI

RenovoRx

Social

Sep 14

Bullish· Aug 15

Bearish· Jun 29

Announcements· Aug 15

Technical Analysis· Nov 11

Sep 9

RenovoRx at H.C. Wainwright conference: commercial growth builds

RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

RenovoRx publishes pharmacokinetic data from Phase III trial

RenovoRx regains Nasdaq minimum bid price compliance

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Also Discussed

RenovoRx, Inc.

Company Information

Location

RenovoRx at H.C. Wainwright conference: commercial growth builds

RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

RenovoRx publishes pharmacokinetic data from Phase III trial

RenovoRx regains Nasdaq minimum bid price compliance

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Also Discussed

Social

Sep 14

Bullish· Aug 15

Bearish· Jun 29

Announcements· Aug 15

Technical Analysis· Nov 11

Sep 9